Shanghai Promotes Clinical Adoption of Innovative Medical Products; Vascular Intervention Leader's IPO Application Accepted

1. Shanghai Promotes the Clinical Use of Innovative Drugs and Medical Devices

Recently, the Shanghai Municipal Commission of Commerce and other 16 departments issued the "Several Measures to Further Expand Service Consumption in Shanghai." According to the Measures, it proposes to enhance the international level of health consumption. Encourage physical examination institutions to extend towards specialized disease examinations and pre- and post-examination services. Apply advanced treatment methods such as cell therapy and brain-computer interfaces to promote the clinical use of innovative technologies and medical devices. Encourage qualified medical institutions to carry out specialized international medical projects. Guide the diversified development of the health industry and address shortages in rehabilitation and nursing resources. Support privately-run medical institutions in providing international medical services. Encourage medical institutions to collaborate with commercial insurance companies for direct settlement of commercial health insurance. Encourage commercial insurance companies to develop health insurance products that align with specialized medical services and cross-border medical insurance products. (IT Home)

2. Information Disclosure Conference of the Inter-Provincial Alliance for the Procurement of Traditional Chinese Medicine Needles Held in Nanning

Recently, the Information Disclosure Conference for the Provincial Alliance's Centralized Bulk Procurement of Medical Consumables in Traditional Chinese Medicine (TCM) Needles was held in Nanning. The conference announced price information from 52 domestic manufacturers, covering 26 provinces, autonomous regions, and municipalities in China. This procurement initiative, led by Guangxi in collaboration with 25 other provinces, autonomous regions, municipalities, and the Xinjiang Production and Construction Corps, focuses on four major categories of TCM needles, including intradermal needles and acupuncture needles. The total procurement volume exceeds 2.5 billion units, representing mainstream demand across China. The procurement process uses a grouped bidding model with multiple rules to compress price ranges, ensuring full transparency. This initiative balances corporate profits with clinical needs, setting an example for the inheritance and innovation of TCM and promoting regional pharmaceutical cooperation and the popularization of appropriate TCM technologies. The procurement cycle lasts for two years, with the possibility of a one-year extension. The selected results are expected to be implemented in the first half of 2026, allowing high-quality and cost-effective products to benefit a wide range of patients. (Xinhua News Agency)

3. Mindray and IVD Enterprises Sign Strategic Cooperation Agreement

Recently, Suzhou Yacoo Technology Co., Ltd. and Shenzhen Mindray Bio-Medical Electronics Co., Ltd. officially signed a strategic cooperation agreement. During the signing ceremony, the senior management of both parties reviewed key aspects such as the supply assurance and technical compatibility of cooperative products like raw materials for in vitro diagnostic reagents. They acknowledged the positive cycle model of "demand-customized development-testing verification-high-quality stable supply" from past collaborations. In the future, the two parties will focus on areas such as artificial intelligence + healthcare and high-end diagnostic technology innovation, deepen R&D collaboration, and accelerate the launch of new products like highly sensitive testing reagent materials. At the same time, they will optimize the supply chain system to enhance global supply responsiveness. Industry synergy, deep integration. (IVD Information)

4. OYMotion Teams Up with Radar to Explore the Embodied Intelligence Track

Recently, at the 10th Anniversary of OYMotion and the Embodied AI Strategic Cooperation Summit, OYMotion Technology Co., Ltd. reached a strategic cooperation agreement with the Radike Group. This collaboration will integrate the industrial chain from basic components to end-effectors, tapping into the trillion-yuan market of embodied artificial intelligence. Since its establishment in 2015, OYMotion has grown from a small team into a high-tech enterprise. In 2017, it launched a fully China-produced intelligent bionic hand; in 2022, it collaborated with the Shanghai University of Traditional Chinese Medicine team to focus on the research and development of neurorehabilitation products, with core products entering the clinical registration phase. In 2024, OYMotion introduced its robotic dexterous hand product, and by 2025, completed three rounds of financing amounting to hundreds of millions of yuan. Participants at the summit noted that as an emerging field with rapid growth, extensive industrial chains, and vast potential, embodied AI is entering its golden age of development. Breakthroughs in core technologies and synergistic industry ecosystems will be key drivers for future progress. (Sina)

5. Dirui Multiple IVD Devices Win Bids at Key Hospitals

Recently, Dirui Healthcare, relying on its self-developed technology, comprehensive solution capabilities, and product performance, successfully won the bidding for the HGFO Hospital's clinical laboratory overall solution project under Ecuador's Ministry of Public Health in collaboration with its exclusive local agent in Ecuador. Dirui Healthcare will provide a tailored integrated clinical laboratory solution for the hospital, including the delivery of core equipment such as the CSM-8000 Biochemistry Immunoassay Assembly Line. The installation and delivery preparations are already underway. HGFO Hospital has stringent selection criteria, and this cooperation signifies the entry of Dirui Healthcare’s high-end laboratory assembly line solutions into the Ecuadorian market, demonstrating the competitiveness of domestically produced high-end medical devices in the international arena and laying a foundation for expanding into the Latin American market. (China Medical Device Procurement Public Service Platform)

6. Unisound Releases "Shanhai KnowMed Large Model 5.0" for the Medical Field

Recently, Unisound released the "Shanhai ‧ Zhiyi Large Model 5.0," an expert large model in the medical field. It establishes a dual-core product system of "Medical Text Large Model + Medical Multi-modal Large Model," comprehensively covering core capabilities such as text processing, intelligent agent collaboration, and multi-modal perception. By integrating diverse functions like medical knowledge Q&A, clinical task planning, and imaging analysis, it forms one of the richest medical AI technical support systems in terms of capability dimensions in the current industry. The medical large model can deeply simulate clinical thinking for complex reasoning, achieving precise differential diagnosis and evidence-based decision-making. Relying on massive high-quality medical data and proprietary knowledge base training, Unisound has reached an excellent level in the industry for core tasks such as medical knowledge Q&A and information extraction. (Zhitong Finance)

7. R&D Design Services Accelerate the Clinical Transformation of Medical Research Achievements

The research and development of medical devices is a complex and rigorous process, involving multiple aspects such as technology, regulations, and clinical practices. OssDsign has a 20,000-square-meter science and innovation center and has established a Medical Device Research Institute dedicated to the clinical transformation of medical research achievements. It boasts a high-level, international, multidisciplinary professional team proficient in the entire process of R&D, regulations, clinical trials, registration, and production, capable of developing and producing various complex and innovative products. With extensive project experience and industry resources, it has built a standardized, regulated, and digitalized full-process service system. It provides one-stop services from preliminary market research, product concept generation, product design and development to prototype production and testing. To date, OssDsign has had over 200 projects enter the review stage, more than 100 projects under development, with a 100% success rate in transformation. (Compiled by OssDsign)

8. IPO Application of Vascular Intervention Leader Accepted

Recently, the official website of the Shenzhen Stock Exchange showed that Biomaterial Medical's ChiNext IPO application has been accepted. The sponsor, auditing, and law firms are China International Capital Corporation, Rongcheng Certified Public Accountants, and Beijing Guofeng Law Firm, respectively. Biomaterial Medical focuses on the research, development, production, and global sales of high-performance vascular interventional medical devices. It is an outstanding enterprise in the field of interventional treatment solutions for complex vascular diseases and China-produced vascular interventional balloon catheters. The company has a comprehensive product system with over 50 series, covering multiple key areas to meet diverse clinical needs. In terms of R&D and production layout, it has established five R&D centers and laboratories, four production bases, and three international operation centers. Its market coverage spans more than 100 countries and regions, establishing a strong brand image. (Medical Device News)